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ABSTRACT
Background: Helicobacter pylori (H. pylori) infection is proposed to be related with autoimmune diseases, 
such as Graves’ disease. This study aimed to assess the association between H. pylori infection and Graves’ 
disease.
Method: A systematic literature review was conducted using Pubmed and Cochrane library. The quality of 
enrolled studies was assessed by the Critical Appraisal Skills Program Oxford. A fixed-effect model approach 
was used if there was no heterogeneity; otherwise, a random-effect model was used. Heterogeneity was assessed 
using I2. Publication bias was assessed by funnel plot. All data were analyzed using REVIEW MANAGER 5.3.
Results: Six studies from Europe and Asia involving 983 patients were included. Overall H. pylori infection 
was significantly associated with Graves’ disease (OR = 2.7; 95% CI: 1.47-4.99; p < 0.001). In subgroup 
analysis of 3 studies using non-serological diagnostic method, the prevalence rate of H. pylori infection was 
higher in Graves’ disease group (78.26% vs. 42.42%) with significant relationship (OR = 4.93; 95% CI: 3.16-
7.69; p < 0.00001; I2 = 0%). The Cytotoxin associated gene A (CagA) antibody prevalence was significantly 
higher in Graves’ disease group (46.57% vs. 20.29%; OR = 4.41; 95% CI: 2.65-7.33; p < 0.00001; I2 = 56%). 
No publication bias was observed.
Conclusion: Our study showed association between H. pylori infection and Graves’ disease. It might suggest 
the need of H. pylori examination in Graves’ disease patients and the impact of H. pylori eradication in the 
treatment of Graves’ disease.
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ABSTRAK
Latar belakang: Beberapa penelitian melaporkan infeksi Helicobacter pylori (H. pylori) berkaitan dengan 
penyakit otoimun, antara lain Graves’ disease. Penelitian ini bertujuan untuk mengevaluasi hubungan antara 
infeksi H. pylori dengan Graves’ disease.
Metode: Telaah literatur dilakukan dengan menggunakan Pubmed dan Cochrane library. Kualitas studi dinilai 
dengan Critical Appraisal Skills Program Oxford. Pendekatan fixed-effect model digunakan jika tidak terdapat 
heterogenitas dan random-effect model digunakan jika terdapat heterogenitas. Heterogenitas dievaluasi dengan 
I2. Bias publikasi dikaji dengan funnel plot. Semua data dianalisis dengan program REVIEW MANAGER 5.3.
Hasil: Enam studi dari Eropa dan Asia meliputi 983 pasien masuk ke dalam kriteria inklusi. Secara 
keseluruhan, infeksi H. pylori secara signifikan berhubungan dengan Graves’ disease (OR = 2.7; 95% CI: 
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1.47-4.99; p < 0.001). Pada analisis subgrup dari 3 studi yang menggunakan metoda diagnostik non-serologik, 
didapatkan prevalensi infeksi H. pylori yang lebih tinggi secara bermakna pada grup Graves’ disease (78.26% 
vs. 42.42%; OR = 4.93; 95% CI: 3.16-7.69; p < 0.00001; I2 = 0%). Prevalensi antibodi CagA secara signifikan 
lebih tinggi pada grup Graves’ disease (46.57% vs. 20.29%; OR = 4.41; 95% CI: 2.65-7.33; p < 0.00001; I2 = 
56%). Tidak ditemukan adanya bias publikasi.
Simpulan: Penelitian ini menunjukkan hubungan antara infeksi H. pylori dengan Graves’ disease. Hal ini 
dapat mendasari perlunya pemeriksaan H. pylori pada pasien Graves’ disease dan dampak eradikasi H. pylori 
dalam terapi Graves’ disease.
Kata kunci: Helicobacter pylori, Graves’ disease, meta-analisis
references cited by the original published studies 
and relevant review articles. Article selection and 
assessment were done by reviewers. We contacted the 
authors via email to obtain the required information 
when relevant information was not available in the 
published article.
Studies were included for analysis based on the 
following inclusion criteria: (i) observational study 
having control group; (ii) the outcome was Graves’ 
disease; (iii) Graves’ disease was diagnosed by the 
presence of hyperthyroidism (suppressed TSH, 
elevated FT3, elevated FT4), diffuse goiter with 
positive antibody titers (TSI, TPOAb, TgAb), and, 
in some cases, opthalmopathy; (iv) the exposure was 
H. pylori infection; (v) the diagnosis of H. pylori 
infection was based on serological tests (antigen-
specific enzyme-linked immunosorbent assay (ELISA) 
and Western blotting) or non-serological tests (rapid 
urease test, stool antigen test (SAT), 13C-urea breath 
test (UBT)); (vi) studies had extractable data and 
sufficient information on the association between H. 
pylori infection and Graves’ disease.
We also recorded the CagA serology examination 
result if it was done in the study. Since all parameter 
observed were objectively measured and having a 
written record, neither recall bias nor observer bias 
were occur in each study. We assessed the quality 
of each study by using the criteria from the critical 
appraisal skills program (CASP) Oxford United 
Kingdom consisting of 11 systematic questions for 
appraising case control study. The quality levels then 
were graded as good, fair, and poor.10 Only studies with 
good quality were included in our final analysis review. 
Discrepancies and disagreements were resolved by 
consensus.
Study characteristics were taken as follows: first 
author; year of publication; study design; country; 
H. pylori test method; subjects characteristics (case 
subjects, age in mean or median, sex, and matched 
INTRODUCTION
Graves’ disease, having thyrotoxicosis as clinical 
hallmark, is characterized by formation of autoantibody 
thyroid stimulating immunoglobulins (TSI) to the 
thyroid stimulating hormone receptor (TSH-R). Other 
antibodies, thyroid peroxidase antibody (TPOAb) and 
thyroglobulin antibody (TgAb), might also present in 
Graves’ disease. The etiology of Graves’ disease is 
considered as a complex combination of genetic and 
environment factors.1,2
The discovery of Helicobacter pylori (H. pylori) 
by Marshall and Warren in 1982 has contributed 
significantly in understanding pathogenesis of diseases. 
Globally, the prevalence of H. pylori infection is 
more than 50%. The impact of this microaerophilic, 
gram negative curved bacillus is not just limited at 
the gastrointestinal; moreover, it has been proposed 
to have extra-gastrointestinal manifestations, such as 
coronary heart disease, diabetes mellitus, autoimmune 
diseases.3-7 The presence of seropositivity to the 
cytotoxin-associated gene A (Cag-A) is commonly 
used to identify the virulence of H. pylori.6,7 
The interaction of H. pylori as infectious 
environmental exposure and genetic susceptibility 
resulting in autoimmune disorder such as Graves’ 
disease has become an appealing issue.1,3,4,8 The present 
study was performed to evaluate the association 
between H. pylori infection and Graves’ disease 
through review of existing studies.
METHOD
We conducted this study according to the meta-
analysis PRISMA guideline (see PRISMA checklist).9 
We performed computerized literature search of 
Cochrane and PubMed database up to July 2015. For 
the search, we limited to humans and used the following 
keywords: “Helicobacter pylori” or “H. pylori”, and 
“Graves’ disease”. We also searched manually related 
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between two groups); CagA test availability; number 
of subjects with positive H. pylori test in each outcome 
group; number of subjects with positive CagA test in 
each outcome group. 
We calculated the odds ratios (OR) with 95% 
confidence interval (CI) for H. pylori positivity. The 
Mantel-Haenszel method was used to weight the studies 
included. A fixed-effect model approach was use if 
there was no heterogeneity; otherwise, a random-effect 
model was used. Heterogeneity was assessed using 
I2. Negative value of I2 was put equal to 0. I2 values 
ranged from 0% (no observed heterogeneity) to 100%, 
and interpreted according to Cochrane Consumers and 
Communication Review Group.11 For sub-analysis, we 
calculated the OR of CagA seropositivity. Moreover, 
to evaluate the possible bias due to difference in 
diagnostic method, we did sub-analysis of the OR of 
H. pylori positivity by serological diagnostic method 
and the OR of H. pylori positivity by non-serological 
diagnostic method (study using both serological and 
non-serological diagnostic method will be included 
here). Publication bias was assessed by funnel plot. 
All statistical analysis was performed using Review 
Manager 5.3. 
RESULTS
Our literature search identified 16 studies, all 
published in English. We excluded studies which 
were not cohort, or case control studies (n = 5), had 
no available information on the association between 
H. pylori infection and Graves’ disease (n = 2), had no 
control group (n = 1). After final-text screening, we 
decided to exclude 1 study due to different baseline 
profile of H. pylori infection and 1 study due to quality 
issue. Finally, a total of 6 studies involving 983 patients 
met our criteria. The flowchart showed the process of 
studies selection (Figure 1).
The studies were published between 1998 and 2013, 
and the characteristics of which are summarized in 
Table. Four studies were performed in Europe, and 
2 studies were performed in Asia.7,8,12-15 Four studies 
had Graves’ disease subjects as a subgroup of the case 
group (subjects with autoimmune thyroid disease) and 
2 other studies had Graves’ disease subjects as the 
whole subjects of case group.7,8,12,15 All studies had 
greater number of female than male subjects in both 
Graves’ disease and control groups. None of the studies 
performed endoscopy due to young age subjects and 
had no alarm symptoms. Three studies used serology 
method, 2 studies used SAT method, and 1 study used 
combination of serology and UBT method12 to assess 
the infection status of H. pylori. Four studies examined 
CagA antibody to identify infection with H. pylori 
strain possessing CagA.7,8,13,14,15 
Figure 1. Flow diagram of literature selection
Table 1. Characteristic of studies included in meta-analysis
Author Year of publication
Study 
design Country HP test method Case subjects
Age  
(mean or median)
De Luis12 1998 CC Spain UBT & ELISA ATD (Graves’ disease as subgroup) patients 33.9 ± 1.2
Larizza14 2006 CC Italy ELISA ATD (Graves’ disease as subgroup) patients 11.7
Bassi7 2010 CC Italy SAT Graves’ disease patients 42.8 ± 8.8
Soveid15 2012 CC Iran ELISA ATD (Graves’ disease as subgroup) patients 36.3 ± 7.6
Bassi13 2012 CC Italy SAT ATD (Graves’ disease as subgroup) patients 48.8 ± 3.9
Wang8 2013 CC China ELISA ATD (Graves’ disease as subgroup) patients 28.0 ± 5.4
CC: Case control; NS: not specified; ATD: Autoimmune thyroid disease
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Table 3. Characteristic of studies included in meta-analysis
Author
HP+
Graves’ 
disease
HP+
control
CagA+
Graves’ 
disease
CagA+
control
De Luis12 13 13 NA NA
Larizza14 8 9 NA NA
Bassi7 88 42 66 20
Soveid15 32 87 20 28
Bassi13 43 43 36 21
Wang8 143 53 75 15
HP: Helicobacter pylori; CagA: cytotoxin associated gene A
Prevalance rate of H. pylori positivity showed 
statistically significant different between Graves’ 
disease and control group in 4 studies.7,8,13,14 One study 
showed higher prevalence of H. pylori positivity in 
Graves’ disease group although it was not statistically 
significant.12 One study, in contrary, showed higher 
prevalence of H. pylori positivity in control group but 
not statistically significant.15 The overall prevalence 
rate of H. pylori positivity was 69.87% (327 of 468) 
in Graves’ disease group and 47.96% (247 of 515) in 
control group. Positivity of H. pylori infection was 
significantly associated with Graves’ disease (pooled 
OR = 2.7; 95% CI: 1.47-4.99; test for overall effect Z 
= 3.18; p < 0.001). However, there was a substantial 
heterogeneity (I2 = 74%).
We performed subgroup analysis of study using 
different method of diagnostic test. In the 3 studies 
using serological diagnostic method, the prevalence 
rate of H. pylori infection was higher in Graves’ 
disease than in control group (64.43% [183 of 284] vs. 
52.46% [149 of 284]). However, the association was 
not significant (pooled OR = 1.61 [95% CI: 0.85-3.06, 
test for overall effect Z = 1.47, p 0.14]) with moderate 
heterogeneity (I2 = 52%) (Figure 2).
In the 3 studies using non-serological diagnostic 
method, the prevalence rate of H. pylori infection 
was also higher in Graves’ disease group than in 
control group (78.26% [144 of 184] vs. 42.42% [98 
of 231]). Moreover, the relationship was statistically 
significant (pooled OR = 4.93 [95% CI: 3.16-7.69, test 
for overall effect Z = 7.03, p < 0.00001]). There was 
no heterogeneity existed (I2 = 0%) (Figure 3).
The CagA antibody prevalence in the pooled 4 
studies was higher in Graves’ disease group (46.57% 
[197 of 423]) than in control group (20.29% [84 of 
414]) with significant OR = 4.41 (95% CI: 2.65-7.33), 
test for overall effect Z = 5.70, p < 0.00001). The 
heterogenity was moderate (I2 = 56%) (Figure 4).
Table 2. Characteristic of studies included in meta-analysis
Author Sex (F/M)Graves’ disease
Sex (F/M)
Control
Matched between case & control CagA testAge Sex S SE Area
De Luis12 13/7 21/10 Yes Yes Yes NA Yes NA
Larizza14 23/2 55/15 Yes Yes NA NA Yes NA
Bassi7 98/14 87/13 Yes Yes Yes Yes Yes A
Soveid15 38/5 89/23 Yes Yes NA Yes Yes A
Bassi13 48/4 90/10 Yes Yes Yes Yes Yes A
Wang8 122/94 59/43 Yes Yes Yes NA Yes A
HP: Helicobacter pylori; F: female; M: male; A: available; NA: not available; S: smoking; SE: socioeconomic; ELISA: enzyme-linked 
immunosorbent assay; UBT: 13C-urea breath test; SAT: stool antigen test; CagA: cytotoxin associated gene A
Figure 2. Association between H. pylori infection and Graves’ disease in studies using serological diagnostic method
Study or Subgroup
Larizza 2006
Soveid 2012
Wang 2013
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.17; Chi² = 4.20, df = 2 (P = 0.12); I² = 52%
Test for overall effect: Z = 1.47 (P = 0.14)
Events
8
32
143
183
Total
25
43
216
284
Events
9
87
53
149
Total
70
112
102
284
Weight
22.2%
31.1%
46.7%
100.0%
M-H, Random, 95% CI
3.19 [1.07, 9.52]
0.84 [0.37, 1.89]
1.81 [1.12, 2.93]
1.61 [0.85, 3.06]
Graves Control Odds Ratio Odds Ratio
M-H, Random, 95% CI
0.1 0.2 0.5 1 2 5 10
Favours [experimental] Favours [control]
Figure 3. Association between H. pylori infection and Graves’ disease in studies using non-serological diagnostic method
Study or Subgroup
Bassi 2010
Bassi 2012
De Luis 1998
Total (95% CI)
Total events
Heterogeneity: Chi² = 1.57, df = 2 (P = 0.46); I² = 0%
Test for overall effect: Z = 7.03 (P < 0.00001)
Events
88
43
13
144
Total
112
52
20
184
Events
42
43
13
98
Total
100
100
31
231
Weight
52.3%
28.0%
19.6%
100.0%
M-H, Fixed, 95% CI
5.06 [2.78, 9.24]
6.33 [2.79, 14.38]
2.57 [0.80, 8.23]
4.93 [3.16, 7.69]
Graves Control Odds Ratio Odds Ratio
M-H, Fixed, 95% CI
0.1 0.2 0.5 1 2 5 10
Favours [experimental] Favours [control]
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For the overall 6 studies, no evidence of publication 
bias was observed in the funnel plot (Figure 5).
H. pylori cannot differentiate either past or current 
infection. Moreover, the background of H. pylori 
prevalence influences the positive predictive value 
(PPV) of this method, as discussed in the study by 
Soveid in Iran.15-22 We found no significant association 
between H. pylori seropositivity and Graves’ disease in 
this subgroup, as shown by the pooled OR of 3 studies 
using serology method, and moderate heterogeneity. 
In contrary, the association was statistically significant 
in the non-serology method subgroup with 0% 
of heterogeneity. This finding may underline the 
importance of ensuring the infection status (current 
infection) since the antibody itself can persist even 
after eradication therapy. Therefore, either UBT or SAT 
method is considered as the preferred non-invasive 
diagnostic method.
For the subgroup analysis of CagA seropositivity, 
overall studies showed that infection by the more 
virulent strain (CagA seropositive) group was 
significantly correlated with Graves’ disease. The 
possession of CagA plays role in the development 
of Graves’ disease through “antigenic mimicry” and 
cytokines expression.17,19 Different diagnostic kit used 
in each study may contribute to the heterogeneity.
In this study, we had heterogeneous race of subjects, 
consisting of Caucasian (4 studies), Asian Chinese (1 
study), and Asian Iranian (1 study). Genetic factors, 
which may be clustered more in people depending on 
their race might play role in the development of Graves’ 
disease. However, there were just 2 studies specifically 
assessed the genetic factor (HLA alleles), one in 
Caucasian and one in Asian Chinese. Unfortunately, 
the result of both studies was not supporting each 
other.8,14 Additional studies need to be done to confirm 
the specific alleles preventing or increasing risk 
developing of Graves’ disease in correlation with 
H. pylori infection.
To our knowledge, this is the first meta-analysis 
study to investigate the association between H. pylori 
positivity and Graves’ disease. This association might 
give an idea of the need H. pylori examination in 
Study or Subgroup
Bassi 2010
Bassi 2012
Soveid 2012
Wang 2013
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.15; Chi² = 6.77, df = 3 (P = 0.08); I² = 56%
Test for overall effect: Z = 5.70 (P < 0.00001)
Events
66
36
20
75
197
Total
112
52
43
216
423
Events
20
21
28
15
84
Total
100
100
112
102
414
Weight
27.1%
22.5%
23.2%
27.2%
100.0%
M-H, Random, 95% CI
5.74 [3.09, 10.65]
8.46 [3.96, 18.11]
2.61 [1.25, 5.45]
3.09 [1.67, 5.71]
4.41 [2.65, 7.33]
Graves Control Odds Ratio Odds Ratio
M-H, Random, 95% CI
0.1 0.2 0.5 1 2 5 10
Favours [control] Favours [Graves]
Figure 4. Association between CagA seropositivity and Graves’ disease
0.1 0.2 0.5 1 2 5 10
0
0.2
0.4
0.6
0.8
1
OR
SE(log[OR])
Figure 5. Funnel plot analysis of H. pylori infection and Graves’ 
disease
DISCUSSION
Based on meta-analysis of 6 studies, there was a 
significant association between H. pylori positivity 
and Graves’ disease. Graves’ disease, a member of 
autoimmune thyroid disease, arises from the complex 
interaction of genetic susceptibility and environmental 
factor. Infectious agent is one of the environmental 
factors receiving particular attention. Among infectious 
agents, H. pylori infection has been proposed to 
trigger the Graves’ disease by several mechanisms. 
Earlier studies showed that the lipopolysaccharide 
(LPS) of H. pylori has a similar structure with human 
cell surface glycoconjugates Lewis X, Lewis Y. The 
“antigenic mimicry” expression of Lewis determinant 
in LPS is associated with CagA status of the H. pylori 
strain.16-18 This “antigenic mimicry” might induce 
autoimmune response which influences the thyroid 
gland. Interestingly, H. pylori might play role through 
modulation of dendritic cells, T helper cells, resulting 
in expression of proinflammatory cytokines such as 
interferon (IFN)-gamma, interleukin (IL)-10, IL-17.19-21 
We performed subgroup analysis by separating the 
diagnostic methods into serologic and non-serologic. 
As we know, serological examination of antibody to 
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Graves’ disease patients and further investigation 
whether the treatment of H. pylori will positively 
influence the treatment of Graves’ disease. However, 
this study has some potential limitations. First, since 
all studies collected the data of exposure and outcome 
in the same time, temporal relationship could not be 
clearly defined. Second, there were just six studies 
met the criteria and were included the meta-analysis. 
CONCLUSION
Our study showed association between H. pylori 
infection and Graves’ disease. We realize that more 
longitudinal studies with uniform diagnostic method, 
larger sample sizes, and multiethnic are needed for 
better understanding of H. pylori and Graves’ disease 
relationship. 
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